Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:


Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for HKI-357

See Plans and Pricing

« Back to Dashboard

What is the drug development status for HKI-357?

HKI-357 is an investigational drug.

There have been 22 clinical trials for HKI-357. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2009.

The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Puma Biotechnology, Inc., Translational Breast Cancer Research Consortium, and NSABP Foundation Inc.

Recent Clinical Trials for HKI-357
HKI-272 for HER2-Positive Breast Cancer and Brain MetastasesTranslational Breast Cancer Research ConsortiumPhase 2
HKI-272 for HER2-Positive Breast Cancer and Brain MetastasesDana-Farber Cancer InstitutePhase 2
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast CancerPuma Biotechnology, Inc.Phase 2

See all HKI-357 clinical trials

Clinical Trial Summary for HKI-357

Top disease conditions for HKI-357
Top clinical trial sponsors for HKI-357

See all HKI-357 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.